siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model

References

• Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–679.
   PubMed Web of Science ®Google Scholar
• Lu HP, Chao CC. Cancer cells acquire resistance to anticancer drugs: an update. Biomed J. 2012;35:464–472.
   PubMedGoogle Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Glavinas H, Krajcsi P, Cserepes J, et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv. 2004;1:27–42.
   PubMedGoogle Scholar
• Sharom F. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105–127.
   PubMed Web of Science ®Google Scholar
• Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–592.
   PubMed Web of Science ®Google Scholar
• Marin JJ, Briz O, Monte MJ, et al. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets. 2012;12:402–438.
   PubMed Web of Science ®Google Scholar
• Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028–1034.
   PubMed Web of Science ®Google Scholar
• Kim M, Turnquist H, Jackson J, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002;8:22–28.
   PubMed Web of Science ®Google Scholar
• Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99:507–512.
   PubMed Web of Science ®Google Scholar
• Liu Y, Peng H, Zhang JT. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol Pharmacol. 2005;68:430–438.
   PubMed Web of Science ®Google Scholar
• Hui RC, Francis RE, Guest SK, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008;7:670–678.
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Jada SR, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007;8:567–575.
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Sandanaraj E, et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99:816–823.
   PubMed Web of Science ®Google Scholar
• Turton NJ, Judah DJ, Riley J, et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene. 2001;20:1300–1306.
   PubMed Web of Science ®Google Scholar
• Noguchi K, Katayama K, Mitsuhashi J, et al. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009;61:26–33.
   PubMed Web of Science ®Google Scholar
• Singhal SS, Singhal J, Nair MP, et al. Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007;30:717–725.
   PubMed Web of Science ®Google Scholar
• Greaves W, Xiao L, Sanchez-Espiridion B, et al. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol. 2012;5:47.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–2879.
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Zhang J, Honbo N, et al. Doxorubicin cardiomyopathy. Cardiology. 2010;115:155–162.
   PubMed Web of Science ®Google Scholar
• Kaczmarek A, Brinkman BM, Heyndrickx L, et al. Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J Pathol. 2012;226:598–608.
   PubMed Web of Science ®Google Scholar
• Colabufo NA, Berardi F, Contino M, et al. ABC pumps and their role in active drug transport. CTMC. 2009;9:119–129.
   Google Scholar
• Zaman GJ, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA. 1994;91:8822–8826.
   PubMed Web of Science ®Google Scholar
• Han B, Zhang JT. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents. 2004;4:31–42.
   PubMedGoogle Scholar
• Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine. 2009;5:8–20.
   PubMed Web of Science ®Google Scholar
• Ryther RC, Flynt AS, Phillips JA 3rd, et al. siRNA therapeutics: big potential from small RNAs. Gene Ther. 2005;12:5–11.
   PubMed Web of Science ®Google Scholar
• van de Water FM, Boerman OC, Wouterse AC, et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34:1393–1397.
   PubMed Web of Science ®Google Scholar
• Chowdhury EH, Maruyama A, Kano A, et al. pH-sensing nano-crystals of carbonate apatite: effects on intracellular delivery and release of DNA for efficient expression into mammalian cells. Gene. 2006;376:87–94.
   PubMed Web of Science ®Google Scholar
• Chowdhury EH. pH-sensitive nano-crystals of carbonate apatite for smart and cell-specific transgene delivery. Expert Opin Drug Deliv. 2007;4:193–196.
   PubMed Web of Science ®Google Scholar
• Chowdhury EH, Akaike T. High performance DNA nano-carriers of carbonate apatite: multiple factors in regulation of particle synthesis and transfection efficiency. Int J Nanomedicine. 2007;2:101–106.
   PubMed Web of Science ®Google Scholar
• Chowdhury EH. Self-assembly of DNA and cell-adhesive proteins onto pH-sensitive inorganic crystals for precise and efficient transgene delivery. Curr Pharm Des. 2008;14:2212–2228.
   PubMed Web of Science ®Google Scholar
• Chowdhury EH, Akaike T. Bio-functional inorganic materials: an attractive branch of gene-based nano-medicine delivery for 21st century. Curr Gene Ther. 2005;5:669–676.
   PubMed Web of Science ®Google Scholar
• Chowdhury EH, Akaike T. A bio-recognition device developed onto nano-crystals of carbonate apatite for cell-targeted gene delivery. Biotechnol Bioeng. 2005;90:414–421.
   PubMed Web of Science ®Google Scholar
• Hossain S, Stanislaus A, Chua MJ, et al. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release. 2010;147:101–108.
   PubMed Web of Science ®Google Scholar
• Li YT, Chua MJ, Kunnath AP, et al. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomedicine. 2012;7:2473–2481.
   PubMedGoogle Scholar
• Stanislaus A, Kunnath AP, Tiash S, et al. Intracellular delivery of NF-κB small interfering RNA for modulating therapeutic activities of classical anti-cancer drugs in human cervical cancer cells. Drugs Ther Stud. 2013;3:7–32.
   Google Scholar
• Stanislaus A, Bakhtiar A, Salleh D, et al. Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel. Cancer Cell Int. 2012;12:30.
   PubMed Web of Science ®Google Scholar
• Chua MJ, Tiash S, Fatemian T, et al. Carbonate apatite-facilitated intracellular delivery of c-ROS1 small interfering RNA sensitises MCF-7 breast cancer cells to cisplatin and paclitaxel. OA Cancer. 2013;1:9.
   Google Scholar
• Tiash S, Othman I, Rosli R, et al. Methotrexate- and cyclophosphamide-embedded pure and strontium substituted carbonate apatite nanoparticles for augmentation of chemotherapeutic activities in breast cancer cells. Curr Drug Deliv. 2014;11:214–222.
   PubMed Web of Science ®Google Scholar
• Kunnath AP, Tiash S, Fatemian T, et al. Intracellular delivery of ERBB2 siRNA and p53 gene synergistically inhibits the growth of established tumor in an immunocompetent mouse. J Cancer Sci Ther. 2014;6:99–104.
   Google Scholar
• Tiash S, Chowdhury EH. Passive targeting of cyclophosphamide-loaded carbonate apatite nanoparticles to liver impedes breast tumor growth in a syngeneic model. Curr Pharm Des. 2016.
   PubMed Web of Science ®Google Scholar
• Mozar FS, Chowdhury EH. Gemcitabine interacts with carbonate apatite with concomitant reduction in particle diameter and enhancement of cytotoxicity in breast cancer cells. Curr Drug Deliv. 2015.
   PubMed Web of Science ®Google Scholar
• Janes KA, Fresneau MP, Marazuela A, et al. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73:255–267.
   PubMed Web of Science ®Google Scholar
• Hossain S, Yamamoto H, Chowdhury EH, et al. Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: effect on growth retardation of established colon tumor. PLoS One. 2013;8:e60428.
   PubMed Web of Science ®Google Scholar
• Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997;89:917–931.
   PubMedGoogle Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95:15665–15670.
   PubMed Web of Science ®Google Scholar
• Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001;42:1007–1017.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Filkowski JN, Tryndyak VP, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010;127:1785–1794.
   PubMed Web of Science ®Google Scholar
• Bao L, Haque A, Jackson K, et al. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol. 2011;178:838–852.
   PubMed Web of Science ®Google Scholar
• Kruger JA, Kaplan CD, Luo Y, et al. Characterization of stem cell-like cancer cells in immune-competent mice. Blood. 2006;108:3906.
   PubMed Web of Science ®Google Scholar
• Saxena M, Stephens MA, Pathak H, et al. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179.
   PubMed Web of Science ®Google Scholar
• Khan AA, Betel D, Miller ML, et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol. 2009;27:549–555.
   PubMed Web of Science ®Google Scholar
• Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537–541.
   PubMed Web of Science ®Google Scholar
• Castanotto D, Sakurai K, Lingeman R, et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 2007;35:5154–5164.
   PubMed Web of Science ®Google Scholar
• Hutvagner G, Simard MJ, Mello CC, et al. Sequence-specific inhibition of small RNA function. PLoS Biol. 2004;2:E98.
   PubMed Web of Science ®Google Scholar
• Vickers TA, Lima WF, Nichols JG, et al. Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res. 2007;35:6598–6610.
   PubMed Web of Science ®Google Scholar
• Koller E, Propp S, Murray H, et al. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res. 2006;34:4467–4476.
   PubMed Web of Science ®Google Scholar
• Kanagasabai R, Krishnamurthy K, Druhan LJ, et al. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. J Biol Chem. 2011;286:33289–33300.
   PubMed Web of Science ®Google Scholar
• Pan YZ, Zhou A, Hu Z, et al. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 2013;41:1744–1751.
   PubMed Web of Science ®Google Scholar
• Peer D, Dekel Y, Melikhov D, et al. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004;64:7562–7569.
   PubMed Web of Science ®Google Scholar
• Stein WD, Cardarelli C, Pastan I, et al. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol. 1994;45:763–772.
   PubMed Web of Science ®Google Scholar
• Garcia-Escarp M, Martinez-Munoz V, Sales-Pardo I, et al. Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs. Cytometry. 2004;62A:129–138.
   Google Scholar
• Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 2004;40:852–857.
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 1999;17:343–359.
   PubMed Web of Science ®Google Scholar
• Persson CU, von Stedingk K, Bexell D, et al. Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum. Sci Rep. 2017;7:10274.
   PubMed Web of Science ®Google Scholar